Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Zytronic to delist from AIM ahead of orderly wind-down

(Sharecast News) - Touch sensor tech firm Zytronic, which announced an orderly wind-down of the company last week, has reassured shareholders that they should receive above-market prices for their stakes, according to its estimates. After conducting a strategic review last year and exploring a sale of the company, Zytronic said on 19 February that it was unable to agree on "suitably attractive terms" for a transaction.

The firm has now decided to cease trading and is currently finalising a possible production schedule for closure, it said on Wednesday.

The stock dropped sharply last week, finishing Tuesday's session at just 40.2p, down more than a quarter over the year-to-date and around half the price it was this time last year.

However, ahead of a proposed de-listing of the stock, the company engaged with advisory firm FRP Advisory with a view to maximise returns to shareholders, and revealed on Wednesday that shareholders can expect to receive an estimated return of 46p per share "in a conservative scenario". That would increase to 60p, "should prevailing asset valuations hold through the wind-down period", it said.

With the company not expecting to be able to publish its results for the fiscal year ending 30 September within the six-month deadline required by AIM rules, shares are likely to be suspended from trade on 1 April.

The stock was up 6% at 42.5p by 1107 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.